drugset / Trial / NCT05215470
CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy
Phase 2
Active not recruiting
100 enrolled
Hospital das Clínicas de Ribeirão Preto
Bristol-Myers Squibb · collabFundação de Amparo à Pesquisa do Estado de São Paulo · collab
NaSingle-groupOpen-labelTreatment
Summary
The study is studying the joint contribution and interactions of germline variants and somatic mutations and their impact on Renal Cell Carcinoma (RCC) development and treatment (immunotherapy).
Timeline
- Start
- 2022-01-18
- Primary completion
- 2024-11-30
- Completion
- 2026-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |